Profile cover photo
Profile photo
Pluristem Therapeutics Inc.
1 follower -
Pluristem Therapeutics Inc. (NasdaqCM: $PSTI, TASE: PSTI/PLTR) is a clinical-stage biotherapy company developing placenta-based cell therapy products.
Pluristem Therapeutics Inc. (NasdaqCM: $PSTI, TASE: PSTI/PLTR) is a clinical-stage biotherapy company developing placenta-based cell therapy products.

1 follower
About
Pluristem Therapeutics Inc.'s posts

Post has attachment
#Claudication symptoms may include pain or discomfort in your feet, calves, thighs, hips or buttocks http://mayocl.in/2kIiJQD @MayoClinic

Post has attachment
Pluristem's PLX-PAD program was selected as part of the European Medicines Agency’s (EMA) adaptive pathways pilot project, aimed at improving timely access for patients to new medicines in areas of high medical need. Find additional information on the program here:

Post has attachment
14 million people in the U.S. are treated for intermittent claudication, blockages in the arteries that reduce blood flow. PLX-PAD may present an alternative treatment option by stimulating the body to grow new arteries in the leg to bypass the blocked ones.

Post has attachment
Pluristem reported financial update and corporate and clinical developments for the second quarter of fiscal 2017, ended December 31, 2016. Read today's press release for clinical and corporate highlights and upcoming milestones:

Post has attachment
Pluristem recently completed enrollment of our Phase 2 intermittent claudication trial. Learn about PLX-PAD cells for IC here:

Post has attachment

Post has attachment

Post has attachment

Post has attachment
Pluristem Announces Bought Deal Offering

Post has attachment
In Critical Limb Ischemia (CLI), fatty deposits block arteries in the leg creating an immediate risk for limb amputation and death.
Wait while more posts are being loaded